Biomedcode Hellas SA was established in 2006 as a spin-off company of BSRC Fleming in order to promote effective exploitation of Fleming researcher's results. Biomedcode is a highly innovative Contract Research Organization (CRO) which provides preclinical drug evaluation services to small and large pharmaceutical companies worldwide. Biomedcode’s human TNF transgenic models were instrumental in providing in vivo proof of principle on the role of deregulated TNF production underlying the development of chronic polyarthritis and for providing the preclinical rationale for the development of anti-TNF therapies for arthritis.Using a unique collection of mouse models that mimic human inflammatory diseases, such as Rheumatoid Arthritis, Intestinal Inflammation, Multiple Sclerosis, psoriasis and others, Biomedcode is offering a diverse array of state-of-the-art evaluation platforms ideal for the preclinical testing of therapeutics against human diseases. Biomedcode’s services combine scientific consulting and custom-tailored solutions towards optimizing the validation procedure of novel and biosimilar pharmaceuticals, as well as the development of novel therapeutic modalities. Through a highly active R&D department and its participation in several large-scale European and National projects, the company also aims to generate novel humanized preclinical evaluation platforms for testing the efficacy of therapeutics targeting an extended range of diseases.